#AMLWorldAwarenessDay 🌏🩸

Check out our recent interview with Eva Telzerow & Klaus Metzeler, who present their new comprehensive study, which will investigate long-term survivorship outcomes in AML:

🎥 buff.ly/dRcbipg

#AMLsm #Leusm #HemOnc #ISAL2025

MYC is required for tumor maintenance & presents a potential target for the treatment of acute leukemias.🩸

Learn about the development of strategies targeting MYC from Michael Andreeff:

👉 buff.ly/IY0vaTp 👈

#Leusm #AMLsm #ALLsm #ISAL2025 #HemOnc #Hematology #MedSky #BloodSky #HemeSky

What factors should be considered when selecting patients with AML for alloSCT? What strategies are being explored to improve post-transplant outcomes in these patients?

Fabio Giglio discussed this at #ISAL2025:

👉 buff.ly/w6wJyYg

#AMLsm #Leusm #BMTsm #Hematology #MedSky #BloodSky #HemeSky

Watch our insightful interview from #ISAL2025 with Sylvie Freeman, who comments on the value of flow-based MRD in monitoring patients with AML:

🎥 buff.ly/4GJaB1n

#AMLsm #Leusm #HemOnc #Hematology #MedSky #BloodSky #HemeSky

#ISAL2025 | Monica Cusan provides insight into organ infiltration in AML, highlighting current treatment approaches and the need for better diagnostic tools to identify extramedullary manifestations:

🎥 buff.ly/XejWcGi

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

We've just got back from #ISAL2025 and will be sharing our exclusive content with you!🎥🩸

Hear from Cristina Papayannidis, who discussed a Phase I/II trial of liposomal annamycin with cytarabine for the treatment of AML:
👉 buff.ly/M5Woufd

#AMLsm #Leusm #Leukemia #CTSM #HemOnc

It’s always a pleasure to speak with ⁦Maria Teresa Voso - today she spoke about how we should treat APL, when and how we should use molecular testing in AML, and more!

Coming soon to vjhemonc.xn--com-wi13b

#ISAL2025 #HemOnc #AMLsm #Leusm

We just spoke with Dennis Görlich at #ISAL2025, who discussed his research on characterizing overall survival in AML and parenthood after AML.

Full interview coming soon to vjhemonc.xn--com-wi13b

#AML #Leukemia #HemOnc

We just spoke to Monica Cusan at #ISAL2025, who shared her study on the functional and phenotypical heterogeneity of leukemic cells infiltrating different organs in AML and advised on managing extramedullary disease.

#AML #Leukemia #HemOnc

We just had a great discussion with Dr Curtis Lachowiez and Prof. Daniel Pollyea on mechanisms of venetoclax resistance in AML and strategies being explored to overcome them🩸🔬

Stay tuned on vjhemonc.com for this exclusive session!

#ISAL2025 #HemOnc #AML #Leukemia

Our first interview at #ISAL2025 was with Cristina Papayannidis, who discussed findings from a trial investigating liposomal annamycin with cytarabine for the treatment of AML, managing patients with extramedullary disease, and more!

Full interview coming soon to VJHemOnc.com!

#AML #Leukemia